During the last session, Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s traded shares were 1.07 million, with the beta value of the company hitting 0.66. At the end of the trading day, the stock’s price was $6.28, reflecting an intraday gain of 1.45% or $0.09. The 52-week high for the YMAB share is $20.90, that puts it down -232.8 from that peak though still a striking 4.3% gain since the share price plummeted to a 52-week low of $6.01. The company’s market capitalization is $281.27M, and the average intraday trading volume over the past 10 days was 0.39 million shares, and the average trade volume was 319.36K shares over the past three months.
Y-Mabs Therapeutics Inc (YMAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.46. YMAB has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.12.
Y-Mabs Therapeutics Inc (NASDAQ:YMAB) trade information
Y-Mabs Therapeutics Inc (YMAB) registered a 1.45% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.45% in intraday trading to $6.28, hitting a weekly high. The stock’s 5-day price performance is -1.72%, and it has moved by -26.72% in 30 days. Based on these gigs, the overall price performance for the year is -35.72%. The short interest in Y-Mabs Therapeutics Inc (NASDAQ:YMAB) is 3.56 million shares and it means that shorts have 9.85 day(s) to cover.
The consensus price target of analysts on Wall Street is $24, which implies an increase of 73.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $24 respectively. As a result, YMAB is trading at a discount of -282.17% off the target high and -282.17% off the low.
Y-Mabs Therapeutics Inc (YMAB) estimates and forecasts
Statistics show that Y-Mabs Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Y-Mabs Therapeutics Inc (YMAB) shares have gone down -50.98% during the last six months, with a year-to-date growth rate less than the industry average at -30.61% against 16.50. In the rating firms’ projections, revenue will increase 4.47% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 26.94M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 24.37M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 23.36M and 19.93M respectively. In this case, analysts expect current quarter sales to grow by 15.33% and then jump by 22.28% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 20.06%. While earnings are projected to return -27.74% in 2025.
YMAB Dividends
Y-Mabs Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Y-Mabs Therapeutics Inc (NASDAQ:YMAB)’s Major holders
Y-Mabs Therapeutics Inc insiders own 12.21% of total outstanding shares while institutional holders control 72.17%, with the float percentage being 82.20%. PARADIGM BIOCAPITAL ADVISORS LP is the largest shareholder of the company, while 165.0 institutions own stock in it. As of 2024-06-30, the company held over 3.87 million shares (or 8.8411% of all shares), a total value of $46.76 million in shares.
The next largest institutional holding, with 2.94 million shares, is of BLACKROCK INC.’s that is approximately 6.7126% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $35.5 million.
